Improving CSF Biomarkers’ Performance for Predicting Progression from Mild Cognitive Impairment to Alzheimer’s Disease by Considering Different Confounding Factors: A Meta-Analysis

Background: Cerebrospinal fluid (CSF) biomarkers’ performance for predicting conversion from mild cognitive impairment (MCI) to Alzheimer’s disease (AD) is still suboptimal. Objective: By considering several confounding factors we aimed to identify in which situations these CSF biomarkers can be useful. Data Sources: A systematic review was conducted on MEDLINE, PreMedline, EMBASE, PsycInfo, CINAHL, Cochrane, and CRD (1990–2013). Eligibility Criteria: (1) Prospective studies of CSF biomarkers’ performance for predicting conversion from MCI to AD/dementia; (2) inclusion of Aβ42 and T-tau and/or p-tau. Several meta-analyses were performed. Results: Aβ42/p-tau ratio had high capacity to predict conversion to AD in MCI patients younger than 70 years. The p-tau had high capacity to identify MCI cases converting to AD in ≤24 months. Conclusions: Explaining how different confounding factors influence CSF biomarkers’ predictive performance is mandatory to elaborate a definitive map of situations, where these CSF biomarkers are useful both in clinics and research.

[1]  P. Scheltens,et al.  Biochemical diagnosis of Alzheimer's disease , 2000, Neurobiology of Aging.

[2]  N. Laird,et al.  Meta-analysis in clinical trials. , 1986, Controlled clinical trials.

[3]  Henrik Zetterberg,et al.  Cerebrospinal fluid markers for prediction of Alzheimer's disease , 2003, Neuroscience Letters.

[4]  Sanfeliu,et al.  [15 years later]. , 1993, Revista de enfermeria.

[5]  K. Blennow,et al.  Multicenter assessment of CSF-phosphorylated tau for the prediction of conversion of MCI , 2007, Neurology.

[6]  Giovanni B. Frisoni,et al.  Consensus report of the working group on: 'Molecular and biochemical markers of Alzheimer's disease' , 1998 .

[7]  Amyloid imaging and CSF biomarkers in predicting cognitive impairment up to 7.5 years later , 2013, Neurology.

[8]  W. M. van der Flier,et al.  Prediction of Alzheimer disease in subjects with amnestic and nonamnestic MCI , 2013, Neurology.

[9]  P. Calabresi,et al.  Performance of aβ1-40, aβ1-42, total tau, and phosphorylated tau as predictors of dementia in a cohort of patients with mild cognitive impairment. , 2012, Journal of Alzheimer's disease : JAD.

[10]  Lucilla Parnetti,et al.  Diagnosing prodromal Alzheimer's disease: Role of CSF biochemical markers , 2006, Mechanisms of Ageing and Development.

[11]  Nick C Fox,et al.  The Diagnosis of Mild Cognitive Impairment due to Alzheimer’s Disease: Recommendations from the National Institute on Aging-Alzheimer’s Association Workgroups on Diagnostic Guidelines for Alzheimer’s Disease , 2011 .

[12]  C. Jack,et al.  Prediction of conversion from mild cognitive impairment to Alzheimer's disease dementia based upon biomarkers and neuropsychological test performance , 2012, Neurobiology of Aging.

[13]  J. Sánchez-Payá,et al.  Biomarkers of Alzheimer′s Disease in the Cerebrospinal Fluid of Spanish Patients With Mild Cognitive Impairment , 2011, Neurochemical Research.

[14]  H. Möller,et al.  Value of CSF β-amyloid1–42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment , 2004, Molecular Psychiatry.

[15]  J. Trojanowski,et al.  CSF α-synuclein improves diagnostic and prognostic performance of CSF tau and Aβ in Alzheimer’s disease , 2013, Acta Neuropathologica.

[16]  A. Wall,et al.  Combination of 18F-FDG PET and cerebrospinal fluid biomarkers as a better predictor of the progression to Alzheimer's disease in mild cognitive impairment patients. , 2013, Journal of Alzheimer's disease : JAD.

[17]  O. Forlenza,et al.  Do CSF total tau, phosphorylated tau, and β-amyloid 42 help to predict progression of mild cognitive impairment to Alzheimer's disease? A systematic review and meta-analysis of the literature , 2008, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.

[18]  N. Qizilbash.  Evidence based dementia practice , 2002 .

[19]  Wiesje M. van der Flier,et al.  CSF biomarker levels in early and late onset Alzheimer's disease , 2009, Neurobiology of Aging.

[20]  E. Tangalos,et al.  Mild Cognitive Impairment Clinical Characterization and Outcome , 1999 .

[21]  Giovanni B. Frisoni,et al.  The Alzheimer’s Association external quality control program for cerebrospinal fluid biomarkers , 2011, Alzheimer's & Dementia.

[22]  R. Nitsch,et al.  Biochemical diagnosis of Alzheimer disease by measuring the cerebrospinal fluid ratio of phosphorylated tau protein to beta-amyloid peptide42. , 2003, Archives of neurology.

[23]  Javier Zamora,et al.  Meta-DiSc : a software for meta-analysis of test accuracy data , 2015 .

[24]  R. Petersen.  Mild cognitive impairment as a diagnostic entity , 2004, Journal of internal medicine.

[25]  K. Blennow,et al.  Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study , 2006, The Lancet Neurology.

[26]  P. Scheltens,et al.  CSF biomarkers and medial temporal lobe atrophy predict dementia in mild cognitive impairment , 2007, Neurobiology of Aging.

[27]  Henrik Zetterberg,et al.  Prediction of Alzheimer’s Disease Using the CSF Aβ42/Aβ40 Ratio in Patients with Mild Cognitive Impairment , 2007, Dementia and Geriatric Cognitive Disorders.

[28]  J. Morris,et al.  The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[29]  D. Rueckert,et al.  Test sequence of CSF and MRI biomarkers for prediction of AD in subjects with MCI , 2012, Neurobiology of Aging.

[30]  Eric Westman,et al.  Combining MRI and CSF measures for classification of Alzheimer's disease and prediction of mild cognitive impairment conversion , 2012, NeuroImage.

[31]  R. Petersen,et al.  Revised Criteria for Mild Cognitive Impairment: Validation within a Longitudinal Population Study , 2006, Dementia and Geriatric Cognitive Disorders.

[32]  M. Verbeek,et al.  Cerebrospinal fluid amyloid beta42/phosphorylated tau ratio discriminates between Alzheimer's disease and vascular dementia. , 2006, The journals of gerontology. Series A, Biological sciences and medical sciences.

[33]  K. Blennow,et al.  Evaluation of CSF biomarkers as predictors of Alzheimer's disease: a clinical follow-up study of 4.7 years. , 2010, Journal of Alzheimer's disease : JAD.

[34]  Hilkka Soininen,et al.  CSF Aβ42 and tau or phosphorylated tau and prediction of progressive mild cognitive impairment , 2005, Neurology.

[35]  P. Deyn,et al.  Improved discrimination of AD patients using β-amyloid(1-42) and tau levels in CSF , 1999, Neurology.

[36]  J Schröder,et al.  Age and diagnostic performance of Alzheimer disease CSF biomarkers , 2012, Neurology.

[37]  K. Blennow,et al.  Prediction and longitudinal study of CSF biomarkers in mild cognitive impairment , 2009, Neurobiology of Aging.

[38]  A. Mitchell,et al.  CSF phosphorylated tau in the diagnosis and prognosis of mild cognitive impairment and Alzheimer’s disease: a meta-analysis of 51 studies , 2009, Journal of Neurology, Neurosurgery & Psychiatry.

[39]  Henrik Zetterberg,et al.  Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia. , 2012, Archives of general psychiatry.

[40]  Jeffrey A. Kaye,et al.  The Oregon Brain Aging Study , 2000, Neurology.

[41]  S. Thompson,et al.  Detecting and describing heterogeneity in meta-analysis. , 1998, Statistics in medicine.

[42]  Manjit,et al.  Neurology , 1912, NeuroImage.

[43]  Sean D Sullivan,et al.  Review and meta-analysis of biomarkers and diagnostic imaging in Alzheimer's disease. , 2011, Journal of Alzheimer's disease : JAD.

[44]  L. Maffei,et al.  Environmental enrichment strengthens corticocortical interactions and reduces amyloid-β oligomers in aged mice , 2013, Front. Aging Neurosci..

[45]  J. Morris,et al.  Current concepts in mild cognitive impairment. , 2001, Archives of neurology.

[46]  C. Jack,et al.  Mild cognitive impairment – beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment , 2004, Journal of internal medicine.

[47]  J. Ioannidis,et al.  The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration , 2009, Annals of Internal Medicine [serial online].

[48]  G. Frisoni,et al.  Supporting evidence for using biomarkers in the diagnosis of MCI due to AD , 2013, Journal of Neurology.

[49]  D. Holtzman,et al.  CSF biomarkers for Alzheimer's disease: current utility and potential future use , 2011, Neurobiology of Aging.

[50]  Nancy Reagan,et al.  Consensus Report of the Working Group on: "Molecular and Biochemical Markers of Alzheimer's Disease" , 1998 .

[51]  Eric Westman,et al.  Meta-Review of CSF Core Biomarkers in Alzheimer’s Disease: The State-of-the-Art after the New Revised Diagnostic Criteria , 2014, Front. Aging Neurosci..

[52]  K. Blennow,et al.  Tau and Abeta42 in cerebrospinal fluid from healthy adults 21-93 years of age: establishment of reference values. , 2001, Clinical chemistry.

[53]  Stefan Klöppel,et al.  BrainAGE in Mild Cognitive Impaired Patients: Predicting the Conversion to Alzheimer’s Disease , 2013, PloS one.

[54]  K. Blennow,et al.  Combination of Hippocampal Volume and Cerebrospinal Fluid Biomarkers Improves Predictive Value in Mild Cognitive Impairment , 2010, Dementia and Geriatric Cognitive Disorders.

[55]  M. Spiegel-Adolf,et al.  Cerebrospinal fluid. , 1965, Progress in neurology and psychiatry.

[56]  H. Merritt,et al.  The cerebrospinal fluid , 1938 .

[57]  W. M. van der Flier,et al.  Tau and p-tau as CSF biomarkers in dementia: a meta-analysis , 2011, Clinical chemistry and laboratory medicine.

[58]  Douglas G. Altman,et al.  Statistical Methods for Examining Heterogeneity and Combining Results from Several Studies in Meta‐Analysis , 2008 .

[59]  Anoop Arunagiri,et al.  CSF Biomarkers for Alzheimer's Disease Diagnosis , 2010, International journal of Alzheimer's disease.

[60]  Stephen F. Carter,et al.  Prediction of dementia in MCI patients based on core diagnostic markers for Alzheimer disease , 2013, Neurology.

[61]  W. M. van der Flier,et al.  CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. , 2009, JAMA.

[62]  J. Schneider,et al.  Neuropathology of older persons without cognitive impairment from two community-based studies , 2006, Neurology.

[63]  D. Moher,et al.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. , 2010, International journal of surgery.

[64]  D. Moher,et al.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. , 2010, International journal of surgery.

[65]  R. Petersen,et al.  Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects , 2009, Annals of neurology.

[66]  J. Sánchez-Payá,et al.  [Biomarkers in the cerebrospinal fluid of patients with mild cognitive impairment: a meta-analysis of their predictive capacity for the diagnosis of Alzheimer's disease]. , 2010, Revista de neurologia.

[67]  H. Chui,et al.  Multicenter clinicopathological correlation in dementia. , 1995, The American journal of psychiatry.

[68]  M. Mendez,et al.  Clinically Diagnosed Alzheimer Disease: Neuropathologic Findings in 650 Cases , 1992, Alzheimer disease and associated disorders.

[69]  J. Touchon,et al.  Classification criteria for mild cognitive impairment , 2001, Neurology.

[70]  A. Fagan,et al.  Comparison of analytical platforms for cerebrospinal fluid measures of β-amyloid 1-42, total tau, and p-tau181 for identifying Alzheimer disease amyloid plaque pathology. , 2011, Archives of neurology.

[71]  Kingshuk Roy Choudhury,et al.  Predicting cognitive decline in subjects at risk for Alzheimer disease by using combined cerebrospinal fluid, MR imaging, and PET biomarkers. , 2013, Radiology.

[72]  Susan Mallett,et al.  QUADAS-2: A Revised Tool for the Quality Assessment of Diagnostic Accuracy Studies , 2011, Annals of Internal Medicine.